Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 4/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2196268 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL20735039 | 0.80 | CHRM2 (0.40) | CHRM2CHRM1CHRM3GPR119KDM4E | |
| SCHEMBL22990242 | 0.80 | CHRM2 (0.40) | CHRM2CHRM1CHRM3GPR119KDM4E | |
| SCHEMBL21142612 | 0.80 | CHRM2 (0.40) | CHRM2CHRM1CHRM3GPR119KDM4E | |
| SCHEMBL17986859 | 0.80 | CHRM2 (0.40) | CHRM2CHRM1CHRM3GPR119KDM4E | |
| SCHEMBL14515887 | 0.77 | CHRM2 (0.38) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL34475689 | 0.77 | CHRM2 (0.38) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL23902504 | 0.77 | CHRM2 (0.39) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL23902506 | 0.77 | CHRM2 (0.39) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL29526186 | 0.76 | NR1H2 (0.38) | CHRM2CHRM1CHRM3KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12344605-B2 | Substituted pyrrolidine amides II | GRUENENTHAL GMBH (DE) | 2025-07-01 | — | — | US | disclosed |
| US-20220127264-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| US-20220127264-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| EP-3728233-B1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-20 | — | — | EP | disclosed |
| EP-3728233-B1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-20 | — | — | EP | disclosed |
| CN-111491931-A | Substituted pyrrolidine amides II | 格吕伦塔尔有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20190185470-A1 | Substituted Pyrrolidine Amides II | GRUENENTHAL GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-20190185470-A1 | Substituted Pyrrolidine Amides II | GRUENENTHAL GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| EP-2152713-B1 | PYRAZOLOPYRROLIDINES AS INHIBITORS OF GAMMA SECRETASE | ELAN PHARM INC (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7977368-B2 | Pyrazolopyrrolidines as inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977368-B2 | Pyrazolopyrrolidines as inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20090099235-A1 | Pyrazolopyrrolidines as Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099235-A1 | Pyrazolopyrrolidines as Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185470-A1 | Substituted Pyrrolidine Amides II | NR3C1, NR3C2, MC2R | CHRM2 964/4885CHRM1 1236/4885CHRM3 1594/4885 |
| US-20220127264-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | NR3C1, NR3C2, MC2R | CHRM2 964/4885CHRM1 1236/4885CHRM3 1594/4885 |
| US-12344605-B2 | Substituted pyrrolidine amides II | NR3C1, NR3C2, MC2R | CHRM2 964/4885CHRM1 1236/4885CHRM3 1594/4885 |
| US-20090099235-A1 | Pyrazolopyrrolidines as Inhibitors of Gamma Secretase | BACE1, BACE2, APP | CHRM2 30/4885CHRM1 36/4885CHRM3 222/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | CHRM2 140/4885CHRM1 165/4885CHRM3 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.